Ovarian cancer biology and immunotherapy
- PMID: 24911597
- DOI: 10.3109/08830185.2014.921161
Ovarian cancer biology and immunotherapy
Abstract
Ovarian cancer is the most lethal malignancy of the female reproductive system and the fifth leading cause of cancer death in women. In the year 2012 alone, United States had 22,280 new ovarian cancer cases and 15,500 deaths were reported. About 7%-10% of ovarian cancers result from an inherited tendency to develop the disease. Ovarian cancer has the ability to escape the immune system because of its pathological interactions between cancer cells and host immune cells in the tumor microenvironment create an immunosuppressive network that promotes tumor growth, protects the tumor from immune system. The levels of immune suppressive elements like regulatory T cells, plasmacytoid dendritic cells and cytokines such as IL-10, IL-6, TNF-α, and TGF-β are elevated in the tumor microenvironment. Vascular endothelial growth factor is known to have an immune suppressing role besides its angiogenic role in the tumor microenvironment. Ovarian cancer is associated with high mortality partly due to difficulties in early diagnosis and development of metastases. These problems may overcome by developing accurate mouse models that should mimic the complexity of human ovarian cancer. Such animal models are better suited to understand pathophysiology, metastases, and also for preclinical testing of targeted molecular therapeutics. Immunotherapy is an area of active investigation and off late many clinical trials is ongoing to prevent disease progression. The main aim of dendritic cells vaccination is to stimulate tumor specific effector T cells that can reduce tumor size and induce immunological memory to prevent tumor relapse.
Keywords: DC vaccines; experimental models; immunotherapy; ovarian cancer; tumor microenvironment.
Similar articles
-
Ovarian cancer creates a suppressive microenvironment to escape immune elimination.Gynecol Oncol. 2010 May;117(2):366-72. doi: 10.1016/j.ygyno.2010.01.019. Epub 2010 Feb 9. Gynecol Oncol. 2010. PMID: 20144842 Review.
-
Emerging immunotherapies in ovarian cancer.Discov Med. 2015 Sep;20(109):97-109. Discov Med. 2015. PMID: 26463091 Review.
-
Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.Int Rev Immunol. 2011 Apr-Jun;30(2-3):71-86. doi: 10.3109/08830185.2011.561507. Int Rev Immunol. 2011. PMID: 21557635 Review.
-
Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?Int Rev Immunol. 2011 Apr-Jun;30(2-3):67-70. doi: 10.3109/08830185.2011.571731. Int Rev Immunol. 2011. PMID: 21557634
-
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.Anticancer Res. 2013 Sep;33(9):3855-9. Anticancer Res. 2013. PMID: 24023319
Cited by
-
Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells.Clin Transl Oncol. 2017 Dec;19(12):1489-1497. doi: 10.1007/s12094-017-1686-2. Epub 2017 Jun 6. Clin Transl Oncol. 2017. PMID: 28589429 Free PMC article.
-
Blood bioactive sphingolipids in patients with advanced serous epithelial ovarian cancer - mass spectrometry analysis.Arch Med Sci. 2018 Jul 10;17(1):53-61. doi: 10.5114/aoms.2018.76996. eCollection 2021. Arch Med Sci. 2018. PMID: 33488856 Free PMC article.
-
γδ T Cell-Mediated Immune Responses in Disease and Therapy.Front Immunol. 2014 Nov 10;5:571. doi: 10.3389/fimmu.2014.00571. eCollection 2014. Front Immunol. 2014. PMID: 25426120 Free PMC article. Review.
-
Clinically relevant microRNAs in ovarian cancer.Mol Cancer Res. 2015 Mar;13(3):393-401. doi: 10.1158/1541-7786.MCR-14-0424. Epub 2014 Oct 10. Mol Cancer Res. 2015. PMID: 25304686 Free PMC article. Review.
-
miR-762 can negatively regulate menin in ovarian cancer.Onco Targets Ther. 2017 Apr 12;10:2127-2137. doi: 10.2147/OTT.S127872. eCollection 2017. Onco Targets Ther. 2017. PMID: 28442921 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical